New to Meducation?
Sign up
Already signed up? Log In
view moderators

DrugInteractions

Category

Www.bmj
1
31

Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity

Polypharmacy, defined as the chronic co-prescription of several drugs, is often the consequence of the application of disease specific guidelines, targeting disease specific goals, to patients with multiple chronic diseases. One common consequence of polypharmacy is the high rate of adverse drug reactions, mainly from drug-drug interactions (the ability of a drug to modify the action or effect of another drug administered successively or simultaneously).1 The risk of a drug-drug interaction in any particular patient increases with the number of co-existing diseases and the number of drugs prescribed.2  
bmj.com
over 4 years ago
Preview
1
13

Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines

Objective To identify the number of drug-disease and drug-drug interactions for exemplar index conditions within National Institute of Health and Care Excellence (NICE) clinical guidelines.  
bmj.com
over 4 years ago
Www.bmj
1
22

Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity

Polypharmacy, defined as the chronic co-prescription of several drugs, is often the consequence of the application of disease specific guidelines, targeting disease specific goals, to patients with multiple chronic diseases. One common consequence of polypharmacy is the high rate of adverse drug reactions, mainly from drug-drug interactions (the ability of a drug to modify the action or effect of another drug administered successively or simultaneously).1 The risk of a drug-drug interaction in any particular patient increases with the number of co-existing diseases and the number of drugs prescribed.2  
bmj.com
over 4 years ago
Preview
1
10

Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines

Objective To identify the number of drug-disease and drug-drug interactions for exemplar index conditions within National Institute of Health and Care Excellence (NICE) clinical guidelines.  
bmj.com
over 4 years ago
Www.bmj
2
72

Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity

Polypharmacy, defined as the chronic co-prescription of several drugs, is often the consequence of the application of disease specific guidelines, targeting disease specific goals, to patients with multiple chronic diseases. One common consequence of polypharmacy is the high rate of adverse drug reactions, mainly from drug-drug interactions (the ability of a drug to modify the action or effect of another drug administered successively or simultaneously).1 The risk of a drug-drug interaction in any particular patient increases with the number of co-existing diseases and the number of drugs prescribed.2  
bmj.com
over 4 years ago
Preview
1
12

Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines

Objective To identify the number of drug-disease and drug-drug interactions for exemplar index conditions within National Institute of Health and Care Excellence (NICE) clinical guidelines.  
bmj.com
over 4 years ago
8
0
188

What are the most important drug interactions with antibiotics?

What are the most important drug interactions with antibiotics?  
sampath kumar
over 6 years ago
Www.bmj
0
37

Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity

Polypharmacy, defined as the chronic co-prescription of several drugs, is often the consequence of the application of disease specific guidelines, targeting disease specific goals, to patients with multiple chronic diseases. One common consequence of polypharmacy is the high rate of adverse drug reactions, mainly from drug-drug interactions (the ability of a drug to modify the action or effect of another drug administered successively or simultaneously).1 The risk of a drug-drug interaction in any particular patient increases with the number of co-existing diseases and the number of drugs prescribed.2  
feeds.bmj.com
over 4 years ago
Www.bmj
0
30

Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines

Objective To identify the number of drug-disease and drug-drug interactions for exemplar index conditions within National Institute of Health and Care Excellence (NICE) clinical guidelines.  
feeds.bmj.com
over 4 years ago
Preview
1
5

CCFA: Biologic Therapies

Biologic therapies are often reserved to treat more advanced or aggressive disease. This section provides information on biologic drugs including the different types, delivery, possible side effects, drug interactions, and special considerations.  
ccfa.org
over 4 years ago
Preview
0
12

Novel oral anticoagulants for the treatment of deep vein thrombosis | Cochrane

Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep vein of the leg or pelvis. It affects approximately 1 in 1000 people. If it is not treated, the clot can travel in the blood and block the arteries in the lungs. This life-threatening condition is called a pulmonary embolism (PE) and occurs in approximately 3 to 4 per 10,000 people. The chances of getting a DVT can be increased if people have certain risk factors. These include previous clots, prolonged periods of immobility (such as travelling on aeroplanes or bed rest), cancer, exposure to oestrogens (pregnancy, oral contraceptives or hormone replacement therapy), trauma and blood disorders such as thrombophilia (abnormal blood clotting). A DVT is diagnosed through determining the risk factors and performing an ultrasound of the leg veins. If a DVT is confirmed, people are treated with an anticoagulant. This medicine prevents further clots from forming. Until recently, the drugs of choice were heparin, fondaparinux and vitamin K antagonists. However, these drugs can cause side effects and have limitations. Two further classes of novel oral anticoagulants have been developed: these are called direct thrombin inhibitors (DTI) and factor Xa inhibitors. There are particular reasons why oral DTIs and factor Xa inhibitors might now be better medicines to use. They can be given orally, they have a predictable effect, they do not require frequent monitoring or re-dosing and they have few known drug interactions. This review measures the effectiveness and safety of these new drugs with conventional treatment.  
cochrane.org
over 4 years ago
Preview
0
22

Drug interactions with warfarin: what clinicians need to know

Remaining vigilant for interactions between medications is a formidable challenge for several reasons. The science of drug interactions is dauntingly complex and constantly evolving, the patient's medication list is often a moving target with prescription and nonprescription elements, and dozens of new drugs arrive at our pharmacies each year, often with incompletely characterized drug interaction profiles.  
cmaj.ca
over 4 years ago
Preview
0
0

Guideline recommended treatments in complex patients with multimorbidity

Multimorbidity is an increasing problem for both clinicians and patients. Aging populations, the increased complexity of managing chronic illness, and the tendency of guidelines to focus on a single disease have created a “perfect storm” of treatment burden. Consider the following patient: “Mrs S is a 79 year old woman with osteoporosis, osteoarthritis, type 2 diabetes mellitus, hypertension, and chronic obstructive pulmonary disease who takes 12 separate drugs in 19 doses five times during a typical day. A drug review revealed three drug-disease interactions, nine drug-drug interactions, and eight potential drug-food interactions.” With this hypothetical case, a decade ago one study showed that the application of multiple guidelines to a patient with multimorbidity creates three problems1: firstly, as comorbidity is a common reason for exclusion in clinical trials it is not known whether treatment effects in patients with multimorbidity are equivalent to those in patients with single diseases.2 3 Secondly, the application of multiple disease oriented guidelines bears the risks of potentially harmful interactions between diseases and treatments.4 5 Thirdly, an uncritical application of multiple guidelines adds to the burden of …  
feeds.bmj.com
about 4 years ago
Preview
0
1

Guideline recommended treatments in complex patients with multimorbidity

Multimorbidity is an increasing problem for both clinicians and patients. Aging populations, the increased complexity of managing chronic illness, and the tendency of guidelines to focus on a single disease have created a “perfect storm” of treatment burden. Consider the following patient: “Mrs S is a 79 year old woman with osteoporosis, osteoarthritis, type 2 diabetes mellitus, hypertension, and chronic obstructive pulmonary disease who takes 12 separate drugs in 19 doses five times during a typical day. A drug review revealed three drug-disease interactions, nine drug-drug interactions, and eight potential drug-food interactions.” With this hypothetical case, a decade ago one study showed that the application of multiple guidelines to a patient with multimorbidity creates three problems1: firstly, as comorbidity is a common reason for exclusion in clinical trials it is not known whether treatment effects in patients with multimorbidity are equivalent to those in patients with single diseases.2 3 Secondly, the application of multiple disease oriented guidelines bears the risks of potentially harmful interactions between diseases and treatments.4 5 Thirdly, an uncritical application of multiple guidelines adds to the burden of …  
feeds.bmj.com
about 4 years ago
Preview
0
0

Guideline recommended treatments in complex patients with multimorbidity

Multimorbidity is an increasing problem for both clinicians and patients. Aging populations, the increased complexity of managing chronic illness, and the tendency of guidelines to focus on a single disease have created a “perfect storm” of treatment burden. Consider the following patient: “Mrs S is a 79 year old woman with osteoporosis, osteoarthritis, type 2 diabetes mellitus, hypertension, and chronic obstructive pulmonary disease who takes 12 separate drugs in 19 doses five times during a typical day. A drug review revealed three drug-disease interactions, nine drug-drug interactions, and eight potential drug-food interactions.” With this hypothetical case, a decade ago one study showed that the application of multiple guidelines to a patient with multimorbidity creates three problems1: firstly, as comorbidity is a common reason for exclusion in clinical trials it is not known whether treatment effects in patients with multimorbidity are equivalent to those in patients with single diseases.2 3 Secondly, the application of multiple disease oriented guidelines bears the risks of potentially harmful interactions between diseases and treatments.4 5 Thirdly, an uncritical application of multiple guidelines adds to the burden of …  
feeds.bmj.com
about 4 years ago
Preview
0
0

Guideline recommended treatments in complex patients with multimorbidity

Multimorbidity is an increasing problem for both clinicians and patients. Aging populations, the increased complexity of managing chronic illness, and the tendency of guidelines to focus on a single disease have created a “perfect storm” of treatment burden. Consider the following patient: “Mrs S is a 79 year old woman with osteoporosis, osteoarthritis, type 2 diabetes mellitus, hypertension, and chronic obstructive pulmonary disease who takes 12 separate drugs in 19 doses five times during a typical day. A drug review revealed three drug-disease interactions, nine drug-drug interactions, and eight potential drug-food interactions.” With this hypothetical case, a decade ago one study showed that the application of multiple guidelines to a patient with multimorbidity creates three problems1: firstly, as comorbidity is a common reason for exclusion in clinical trials it is not known whether treatment effects in patients with multimorbidity are equivalent to those in patients with single diseases.2 3 Secondly, the application of multiple disease oriented guidelines bears the risks of potentially harmful interactions between diseases and treatments.4 5 Thirdly, an uncritical application of multiple guidelines adds to the burden of …  
feeds.bmj.com
about 4 years ago
Preview
0
0

FDA Asks for Drug Interaction Studies on Kayexalate

The agency's request stems from a review of another potassium binder, the recently approved patiromer (Veltassa), which found drug-drug interactions in more than half of the medications tested.  
medscape.com
about 4 years ago
Preview
0
1

Warfarin, Sulfonylurea Combo Ups Severe Hypoglycemia Risk

The findings suggest a unique drug-drug interaction between warfarin and glipizide/glimepiride, with the greatest hypoglycemia risk at start of warfarin treatment.  
medscape.com
almost 4 years ago
Preview
0
3

Drug-Drug Interactions With New HCV Medications

Many patients taking direct acting antivirals (DAA) to treat hepatitis C virus (HCV) are at risk of clinically significant drug-drug interactions (DDIs), new research shows.  
medscape.com
almost 4 years ago